MediWound Ltd. (MDWD) – What Are Brokerages Thinking About This Stock?

Shares of MediWound Ltd. (NASDAQ:MDWD) have received an average recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $33.00.

MDWD has been the topic of a number of analyst reports. TD Cowen reiterated a “buy” rating on shares of MediWound in a research report on Thursday, September 24th. Alliance Global Partners reissued a “buy” rating on shares of MediWound in a research note on Wednesday, September 16th. Wall Street Zen upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a report on Saturday, September 26th. Weiss Ratings cut shares of MediWound from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $30.00 target price (down from $32.00) on shares of MediWound in a research note on Friday, August 14th.

Insider Buying and Selling at MediWound

In other news, COO Shmuel Hess sold 3,958 shares of MediWound stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.92, for a total transaction of $51,137.36. The sale was disclosed in a legal filing with the SEC, which is available through this link. 9.20% of the stock is currently owned by corporate insiders.

MediWound Trading Up 6.0%

Shares of MDWD opened at $14.20 on Thursday. MediWound has a 1 year low of $11.80 and a 1 year high of $19.70. The stock has a market cap of $182.47 million, a P/E ratio of -7.89 and a beta of 0.07. The stock’s 50-day moving average price is $13.09 and its two-hundred day moving average price is $15.18.

MediWound (NASDAQ:MDWD) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.01). The company had revenue of $3.09 million for the quarter, compared to analyst estimates of $2.59 million. MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%. As a group, equities analysts forecast that MediWound will post -2.37 EPS for the current year.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds.

MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.